Printer Friendly
The Free Library
22,741,889 articles and books

Targeted Genetics to Present at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference.

SEATTLE -- Targeted Genetics Corporation (Nasdaq: TGEN TGEN Traffic Generator
TGEN Table Generate
TGEN Test Generator
) will be presenting at the Rodman & Renshaw TechVest 7th Annual Healthcare Conference on Tuesday, November 8, 2005, at 8:40 a.m. EST EST electroshock therapy.

electroshock therapy
 at the New York Palace
  • Palace Theatre, New York
  • New York Palace, Budapest, Hungary
. H. Stewart Parker, President and Chief Executive Officer, will provide a corporate overview, including an update to the Company's product development programs and recent corporate activities.

To access the live audio webcast for this conference, please log on to Targeted Genetics' website at to register and download any necessary software. The audio presentation and slideshow will be available for replay following the event. Additional information about the Rodman & Renshaw conference can be found at

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need. We use our considerable knowledge and capabilities in the development and manufacturing of gene delivery technologies to advance a diverse product development pipeline. Our product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , Huntington's disease Huntington's disease, hereditary, acute disturbance of the central nervous system usually beginning in middle age and characterized by involuntary muscular movements and progressive intellectual deterioration; formerly called Huntington's chorea.  and hyperlipidemia hyperlipidemia /hy·per·lip·id·emia/ (-lip?i-de´me-ah) elevated concentrations of any or all of the lipids in the plasma, including hypertriglyceridemia, hypercholesterolemia, etc. . To learn more about Targeted Genetics, visit our website at:

Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995:

This release contains forward-looking statements regarding our business strategy, our product development and other statements about our plans, objectives, intentions and expectations. In particular, the statements regarding the Company's future plans are forward-looking statements. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, the timing, enrollment of patients, nature and results of our clinical trials, potential development of alternative technologies or more effective products by competitors, our ability to obtain and maintain regulatory or institutional approvals, our ability to obtain, maintain and protect our intellectual property and our ability to raise capital when needed, as well as other risk factors described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our Quarterly Report on Form 10-Q Form 10-Q

See 10-Q.
 for the period ended June 30, 2005. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 2, 2005
Previous Article:Restoration Force Focuses on 615,000 Customers Remaining out of Power Post-Wilma; FPL Shares Tips to Help Ensure Safe and Quick Restoration.
Next Article:Acusphere Takes Occupancy of Commercial Manufacturing Facility in Tewksbury, Massachusetts.

Related Articles
ZIOPHARM Oncology to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
Inflazyme to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
AVANT To Present At Rodman & Renshaw TechVest Healthcare Conference.
RegeneRx to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
MethylGene to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
Clinical Data to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
Alnylam to Webcast Presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005.
Aphton to Present at Rodman & Renshaw 7th Annual Healthcare Conference.
AVI BioPharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference.
AVANT To Present At Rodman & Renshaw 8th Annual Healthcare Conference.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters